Search research articles
Contact Us
Filters
Showing results (111-120 of 139) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies
Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
Jean-Pascal H Machiels, Stéphanie Henry, Sylvie Zanetta, et al.
Cancer Research
|
May 7, 2009
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells
Aïda Ghoul, Maria Serova, Lucile Astorgues-Xerri, et al.
Journal of Translational Medicine
|
July 27, 2011
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Charles S Harmon, Samuel E DePrimo, Eric Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients
Jérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy
Diane Evrard, Aurélie Beaufrère, Clément Dumont, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 139) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies
Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
Jean-Pascal H Machiels, Stéphanie Henry, Sylvie Zanetta, et al.
Cancer Research
|
May 7, 2009
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells
Aïda Ghoul, Maria Serova, Lucile Astorgues-Xerri, et al.
Journal of Translational Medicine
|
July 27, 2011
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Charles S Harmon, Samuel E DePrimo, Eric Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients
Jérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy
Diane Evrard, Aurélie Beaufrère, Clément Dumont, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Page
of 14